Aaron M Drucker, MD, ScM, FRCPC, FAAD
Disclosures
Drucker reports no relevant financial disclosures.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.Treatment of atopic dermatitis has changed so much in the last 10 years. First biologic was approved in 2017, and since then we've had a steady increase in the number of biologics and JAK inhibitors that have been approved to treat atopic dermatitis systemically. We've also had a number of new topical molecules. The vast majority of people with atopic dermatitis are gonna be treated with topical therapy. And so now we have, in addition to topical corticosteroids and topical calcineurin inhibitors that have been around for a long time, we have topical phosphodiesterase 4 inhibitors, we have topical JAK inhibitors, as well as a topical aryl hydrocarbon receptor agonist. And so we have more options to choose from.
Of course, you know, as dermatologists who are seeing more moderate to severe cases of atopic dermatitis, we tend to focus on those systemic therapies, but there's a lot been happening in topicals as well, and that's where really the majority of patients are gonna benefit.
